Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Operating Leases (2019 - 2024)

BioRestorative Therapies (BRTX) has disclosed Operating Leases for 6 consecutive years, with $42414.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Operating Leases changed 0.0% year-over-year to $42414.0, compared with a TTM value of $42414.0 through Sep 2024, changed 0.0%, and an annual FY2023 reading of $162317.0, changed 0.0% over the prior year.
  • Operating Leases was $42414.0 for Q3 2024 at BioRestorative Therapies, down from $83580.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $544223.0 in Q3 2020 and bottomed at $42414.0 in Q3 2023.
  • Average Operating Leases over 5 years is $252247.4, with a median of $234060.0 recorded in 2022.
  • Peak annual rise in Operating Leases hit 0.0% in 2023, while the deepest fall reached 78.66% in 2023.
  • Year by year, Operating Leases stood at $363519.0 in 2020, then fell by 17.02% to $301645.0 in 2021, then crashed by 46.19% to $162317.0 in 2022, then changed by 0.0% to $162317.0 in 2023, then crashed by 73.87% to $42414.0 in 2024.
  • Business Quant data shows Operating Leases for BRTX at $42414.0 in Q3 2024, $83580.0 in Q2 2024, and $123536.0 in Q1 2024.